Prognostic Utility of Total 68Ga-DOTATATE-Avid Tumor Volume in Patients With Neuroendocrine Tumors

Tirosh, Amit; Papadakis, Georgios Z.; Millo, Corina; Hammoud, Dima A.; Sadowski, Samira M.; Herscovitch, Peter; Pacák, Karel; Marx, Stephen J.; Yang, Liangcheng; Nockel, Pavel; Shell, Jasmine; Green, Patience; Keutgen, Xavier M.; Patel, Dhaval; Nilubol, Naris; Kebebew, Electron

doi:10.1053/j.gastro.2017.11.008

Cited by 73 publications

(77 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Volumetric variables (WTV and TRE) determined by [ 68 Ga]Ga-DOTA-conjugated radiotracer PET/CT were assessed in a previous article, which revealed that the WTV determined by [ 68 Ga]Ga-DOTA-TATE PET/CT is associated with prognosis [33]. However, a limitation of this study was the heterogeneous patient population in terms of treatment, including surgery, PRRT, liver- directed therapy, and systemic therapy.…”

Section: Discussionmentioning

confidence: 99%

Tumour-to-liver ratio determined by [68Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours

Kim

Yoo

et al. 2020

EJNMMI Res

View full text Add to dashboard Cite

Background: Lanreotide is a long-acting somatostatin analogue with proven antitumour effects against well-differentiated (WD) gastroenteropancreatic-neuroendocrine tumours (GEP-NETs). However, there are no globally established prognostic factors associated with the efficacy of lanreotide as a treatment for GEP-NETs. We investigated the prognostic value of [ 68 Ga]Ga-DOTA-TOC positron emission tomography (PET)/computed tomography (CT) somatostatin receptor imaging for patients with WD GEP-NETs treated with lanreotide. Methods: In this retrospective study, we included 31 patients with unresectable or metastatic WD GEP-NETs who received lanreotide and underwent [ 68 Ga]Ga-DOTA-TOC PET/CT before receiving lanreotide. We captured the following clinicopathological variables: Eastern Cooperative Oncology Group (ECOG) performance status, primary tumour site, NET World Health Organization grade, existence of carcinoid symptoms, previous surgery, previous chemotherapy, and hepatic tumour volume assessed by CT or magnetic resonance imaging (MRI). We also assessed the following [ 68 Ga]Ga-DOTA-TOC PET/CT variables: Krenning score, tumour-to-liver ratio (TLR), maximum standardized uptake value (SUVmax), whole tumour volume (WTV), and total receptor expression (TRE, WTV multiplied by SUVmean). The associations between these markers and progression-free survival (PFS) with lanreotide were analysed.

show abstract

Section: Discussionmentioning

confidence: 99%

Tumour-to-liver ratio determined by [68Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours

Kim

Yoo

et al. 2020

EJNMMI Res

View full text Add to dashboard Cite

show abstract

“…Bone FD has been visualized with conventional SSTRs scintigraphy using 111 ln-pentetreotide, suggesting cell surface over-expression of SSTRs by fibrous dysplastic cells (119). The introduction of 68 Ga-DOTA-conjugated-peptides into clinical practice has enabled the employment of PET-imaging in targeting lesions, characterized by SSTRs-overexpressi on (18,(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33). Papadakis et al reported intensely increased 68 Ga-DOTATE (radiolabeled somatostatin analogue suitable for PET-imaging, which targets SSTRs) activity on PET/CT, by a biopsy proven FD lesion in the temporal bone (22).…”

Section: Fibrous Dysplasiamentioning

confidence: 99%

“…68 Ga-DOTA-compounds are somatostatin (SST) analogs, radiolabeled with the positron emitting isotope gallium-68 ( 68 Ga) through the chelator 1,4,7,10-tetraazacyclododecane-1, 4,7,10-tetraacetic acid (DOTA) (18). The employment of these compounds enables highly efficient targeting of lesions which are characterized by cell-surface over-expression of SST receptors (SSTRs), such as neuroendocrine tumors (NETs), for which PET/CT imaging with 68 Ga-DOTA-compounds is evolving as the imaging standard of reference (19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33).…”

Section: Introductionmentioning

confidence: 99%

PET/CT and PET/MRI in ophthalmic oncology (Review)

et al. 2020

Self Cite

View full text Add to dashboard Cite

Orbital and ocular anatomy is quite complex, consisting of several tissues, which can give rise to both benign and malignant tumors, while several primary neoplasms can metastasize to the orbital and ocular space. Early detection, accurate staging and re-staging, efficient monitoring of treat-ment response, non-invasive differentiation between benign and malignant lesions, and accurate planning of external radiation treatment, are of utmost importance for the optimal and individualized management of ophthalmic oncology patients. Addressing these challenges requires the employment of several diagnostic imaging techniques, such as high-definition digital fundus photography, ultrasound imaging, optical coherence tomography, optical coherence tomography (OCT)-angiography, computed tomography (CT) and magnetic resonance imaging (MRI). In recent years, technological advances have enabled the development of hybrid positron emission tomography (PET)/CT and PET/MRI systems, setting new standards in cancer diagnosis and treatment. The capability of simultaneously targeting several cancer-related biochemical procedures using positron emitting-radiopharmaceuticals, while morphologically characterizing lesions by CT or MRI, together with the intrinsic quantitative capabilities of PET-imaging, provide incremental diagnostic information, enabling accurate, highly efficient and personalized treatment strategies. Aim of the current review is to discuss the current applications of hybrid PET/CT and PET/MRI imaging in the management of patients presenting with the most commonly encountered orbital and ocular tumors.

show abstract

“…Scarce pertinent literature reports a significant correlation between whole-body SRETV (SRETVwb) and disease progression after PRRT. Tirosh et al [97] reported that " 68 Ga-DOTATATE TV" (equalling SRETVwb) > 7.0 mL was significantly correlated with a higher risk for disease progression, while " 68 Ga-DOTATATE TV" > 35.8 ml was associated with higher diseasespecific mortality. Toriihara et al [98] reported an association between " 68 Ga DOTATATE ∑SRETV"…”

Section: Functional Imagingmentioning

confidence: 99%

The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future.

Liberini¹,

Hüllner²,

Grimaldi³

et al. 2020

Preprint

View full text Add to dashboard Cite

The NETTER-1 study has proven peptide receptor radionuclide therapy (PRRT) to be one of the most effective therapeutic options for metastatic neuroendocrine tumors (NETs), improving progression-free survival and overall survival. However, PRRT response assessment is challenging and no consensus on methods and timing has yet been reached among experts in the field. This issue is owing to the suboptimal sensitivity and specificity of clinical biomarkers, limitations of morphological response criteria in slowly growing tumors and necrotic changes after therapy, a lack of standardized parameters and timing of functional imaging, and the heterogeneity of PRRT protocols in the literature. The aim of this article is to review the most relevant current approaches for PRRT efficacy prediction and response assessment criteria in order to provide an overview of suitable tools for safe and efficacious PRRT.

show abstract

Prognostic Utility of Total 68Ga-DOTATATE-Avid Tumor Volume in Patients With Neuroendocrine Tumors

Abstract: In a prospective study, we demonstrated the prognostic utility of Ga-DOTATATE TV in a large cohort of patients with NETs, in terms of PFS and disease-specific mortality.

Cited by 73 publications

References 43 publications

Tumour-to-liver ratio determined by [68Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours

Tumour-to-liver ratio determined by [68Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours

PET/CT and PET/MRI in ophthalmic oncology (Review)

The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future.

Contact Info

Product

Resources

About